Patents Issued in April 30, 2019
  • Patent number: 10272064
    Abstract: The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: April 30, 2019
    Assignee: scPharmaceuticals Inc.
    Inventors: Scott A. Michaels, Pieter Muntendam, Glenn R. Larsen
  • Patent number: 10272065
    Abstract: The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podophyllotoxin gem-difluorinated C-glycoconjugated derivatives display improved conformational and chemical stability, and improved cytotoxicity exhibited against drug-resistant cancer cell lines.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: April 30, 2019
    Assignee: Benoit & Côté
    Inventor: Steve N. Slilaty
  • Patent number: 10272066
    Abstract: The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: April 30, 2019
    Inventors: Philippe Diolez, Dominique Detaille, Frédéric Marin, Olivier Petitjean
  • Patent number: 10272067
    Abstract: The present invention relates to pyrrolidone carboxylic acid (PCA) and/or pharmaceutically acceptable salts or derivatives thereof for use in the treatment of ocular diseases and/or disorders. A further object of the present invention are compositions comprising pyrrolidone carboxylic acid (PCA) and/or pharmaceutically acceptable salts or derivatives thereof, at least one physiologically acceptable excipient, and optionally at least one additional active ingredient for use in the treatment of ocular diseases and/or disorders.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: April 30, 2019
    Assignee: Laboratori Baldacci S.p.A.
    Inventor: Massimo Baldacci
  • Patent number: 10272068
    Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: April 30, 2019
    Assignee: Tyme, Inc.
    Inventor: Steven Hoffman
  • Patent number: 10272069
    Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 30, 2019
    Assignee: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO
    Inventors: Dean Burkin, Ryan Wuebbles
  • Patent number: 10272070
    Abstract: The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 30, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO R UNIVERSITY
    Inventors: Khoa Dinh Nguyen, Edgar G. Engleman
  • Patent number: 10272071
    Abstract: The present invention relates to methods of treating or preventing arthropod infestations of poultry animals and methods of controlling arthropod infestations in poultry animal's environment by administering an isoxazoline compound of formula (I) via drinking water.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 30, 2019
    Assignee: Intervet Inc.
    Inventors: Anja Regina Heckeroth, Hartmut Zoller, Annie Flochlay-Sigognault, Bruno Huyghe
  • Patent number: 10272072
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: April 30, 2019
    Assignees: Forma TM, LLC, Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre Joseph Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • Patent number: 10272073
    Abstract: This invention is a prosthetic device generally placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material. Methods of perivascular antiproliferative drug administration also are disclosed.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: April 30, 2019
    Assignee: Vascular Therapies, Inc.
    Inventors: Sriram S. Iyer, Nicholas N. Kipshidze, Victor V. Nikolaychik
  • Patent number: 10272074
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 30, 2019
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Christian A. Hassig, Michael R. Jackson, Robert John Ardecky, Ian Pass
  • Patent number: 10272075
    Abstract: Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: April 30, 2019
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt D. Wolfgang
  • Patent number: 10272076
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: April 30, 2019
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Patent number: 10272077
    Abstract: The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: April 30, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman
  • Patent number: 10272078
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: April 30, 2019
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • Patent number: 10272079
    Abstract: Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: April 30, 2019
    Assignee: ARDELYX, INC.
    Inventors: Christopher Carreras, Dominique Charmot, Jeffrey W Jacobs, Eric Labonte, Jason G. Lewis
  • Patent number: 10272080
    Abstract: Working memory deficits are treated and working memory is improved with a composition that comprises a therapeutically effective amount of one or more respective selective dopamine D4 receptor agonists and/or pharmaceutically acceptable analogs, salts or hydrates of the respective one or more selective dopamine D4 receptor agonists. This composition can be administered to a subject to improve the subject's working memory.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: April 30, 2019
    Assignees: Florida State University Research Foundation, Inc., The General Hospital Corporation
    Inventors: Pradeep G. Bhide, Jinmin Zhu, Joseph Biederman, Thomas J. Spencer
  • Patent number: 10272081
    Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: April 30, 2019
    Assignee: Aquinox Pharmaceuticals (Canada) Inc.
    Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
  • Patent number: 10272082
    Abstract: Provided is a method for treating ALS in a subject, comprising administering to the subject a therapeutically effective amount of riluzole and a therapeutically effective amount of CK-2017357. Also provided are methods of reducing the variability of riluzole exposure (e.g., Cmax and/or AUC24h) in a subject, methods of reducing the variability of riluzole exposure (e.g., Cmax and/or AUC24h) between two or more subjects, methods of decreasing the total daily dose of riluzole in a subject, methods of increasing the half-life of riluzole in a subject, methods for decreasing the frequency of riluzole dosing in the subject, and methods for reducing the incidence and/or severity of adverse events in a subject treated with riluzole.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: April 30, 2019
    Assignee: Cytokinetics, Inc.
    Inventors: Jesse Cedarbaum, John Mao, Fady Malik, Andrew A. Wolff
  • Patent number: 10272083
    Abstract: Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: April 30, 2019
    Assignee: ACERTA PHARMA B.V.
    Inventors: Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Brian Lannutti, Todd Covey, Roger Ulrich, Dave Johnson, Tjeerd Barf, Allard Kaptein
  • Patent number: 10272084
    Abstract: Disclosed are methods for treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: April 30, 2019
    Assignees: Regenacy Pharmaceuticals, LLC, Board of Regents, The University of Texas System
    Inventors: Annemieke Kavelaars, Cobi J. Heijnen, Karen Krukowski, Matthew B. Jarpe
  • Patent number: 10272085
    Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 30, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: David McGowan, Pierre Jean-Marie Bernard Raboisson, Werner Embrechts, Tim Hugo Maria Jonckers, Stefaan Julien Last, Serge Maria Aloysius Pieters, Jaromir Vlach
  • Patent number: 10272086
    Abstract: Methods for treating androgen receptor related diseases and suppressing androgen receptor related function by administering an effective amount of minoxidil are provided. Methods for treating or prophylactically treating acne by administering an effective amount of minoxidil are also provided. An anti-acne medication is optionally administered to treat or prophylactically treat acne.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: April 30, 2019
    Assignees: Chang Gung Memorial Hospital, Linkou
    Inventor: Cheng-Lung Hsu
  • Patent number: 10272087
    Abstract: The invention relates to new pteridine derivative compounds, of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: April 30, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher Charles Frederick Hamlett, Valerio Berdini, Christopher William Murray, Patrick René Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet
  • Patent number: 10272088
    Abstract: The present invention relates to compounds, compositions and methods comprising nanoparticles (NP) that are based on hyaluronic acid (HLA) that have been modified with hydrophobic moieties that can entrap FASN inhibitor compounds. In one embodiment, the FASN inhibitor compounds include Orlistat. In one embodiment, the hydrophobic moieties comprise 5-?CA, Pba, or ODA, or combinations thereof. In a variation, the present invention relates to a composition comprising NPs based upon HLA, Orlistat, one or more of the hydrophobic moieties comprising 5-?CA, Pba, or ODA, and one or more of members selected from the group consisting of PEG and a dilute solution containing SDS.
    Type: Grant
    Filed: July 25, 2015
    Date of Patent: April 30, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Aaron M. Mohs, Steve J. Kridel, Tanner K. Hill
  • Patent number: 10272089
    Abstract: The use of methotrexate, e.g., repeated dosing or sustained-release formulations of methotrexate, for treating or reducing risk of proliferative vitreoretinopathy (PVR) or epiretinal membranes (ERM), e.g., after surgical vitrectomy to treat retinal detachment.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: April 30, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Dean Eliott, Tomasz P. Stryjewski
  • Patent number: 10272090
    Abstract: The present invention relates to a liquid pharmaceutical composition suitable for parenteral administration comprising: a) pemetrexed diacid; b) at least one organic amine; c) at least one antioxidant; d) 10-200 mg/ml of propylene glycol; and e) one or more parenteral solvents, wherein the preparation thereof is conducted in an atmosphere of inert gas and wherein the organic amine(s) is present in an amount sufficient to reach a pH of the composition in the range from 8.3 to 9.1.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: April 30, 2019
    Assignee: Synthon B.V.
    Inventor: Borek Zaludek
  • Patent number: 10272091
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: April 30, 2019
    Assignee: Ortho-Nutra, LLC
    Inventors: Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Patent number: 10272092
    Abstract: The present invention relates to a composition for preventing or treating mucositis comprising NecroX. It was found that NecroX has effects of reducing the disease mortality rate by means of radiotherapy or chemotherapy in a NecroX administration group, protecting intestinal functions, inhibiting destruction of intestinal mucous membrane, and proliferating the cells present in intestines. NecroX may be used for a pharmaceutical composition for preventing or treating mucositis, an anti-cancer adjuvant, or a food composition.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: April 30, 2019
    Assignee: The Catholic University of Korea Industry-Academic Cooperation
    Inventors: Seok Goo Cho, Keon-Il Im, Jung Yeon Lim, Nayoun Kim, Young Sun Nam, Eun Sol Lee
  • Patent number: 10272093
    Abstract: Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 30, 2019
    Assignee: Regents of the University of California
    Inventors: Carl W. Cotman, Larry E. Overman, Shikha Snigdha
  • Patent number: 10272094
    Abstract: Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: April 30, 2019
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Juerg Lehmann, Konrad Feichtinger, Albert S. Ren, Graeme Semple
  • Patent number: 10272095
    Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 30, 2019
    Assignees: GlaxoSmithKline Intellectual Propert Development Limited, Astex Therapeutics, Limited
    Inventors: Jeffrey K. Kerns, James Francis Callahan, Hongxing Yan, Thomas Daniel Heightman, Jeffrey Charles Boehm, Alison Jo-Anne Woolford
  • Patent number: 10272096
    Abstract: The invention generally relates to methods for treating and/or reducing the severity of a wound in a subject. Provided are wound therapies combining low level light therapy (LLLT) and a nitric oxide (NO) donor to treat and/or reduce the severity of the wound. The LLLT and NO donor may be administered concurrently or sequentially. Also provided are wound treatment systems and kits including a light source and a NO donor, which are administered to a wounded subject. Further provided are pharmaceutical compositions that comprise a NO donor and are formulated to be administered in conjunction with LLLT.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 30, 2019
    Inventors: Michael W. Berns, Ryan M. Spitler, Gerard Boss
  • Patent number: 10272097
    Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: April 30, 2019
    Assignees: Virginia Commonwealth University, Durect Corporation
    Inventors: Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
  • Patent number: 10272098
    Abstract: The present invention provides drug delivery compositions that allow for immediate and/or sustained release of a therapeutic agent contained within the system. The present invention also provides drug delivery compositions that preserve the stability of the therapeutic agent contained within during the sustained release. The present invention further provides a method of treating, ameliorating, or preventing an inflammation-related disease or disorder in a subject using the compositions of the invention.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 30, 2019
    Assignee: Drexel University
    Inventors: Yinghui Zhong, Zhiling Zhang
  • Patent number: 10272099
    Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: April 30, 2019
    Assignees: The Board of Regents of the University of Texas System, The Board of Trustees of the University of Illinois.
    Inventors: Paul J. Hergenrother, David A. Boothman, Joseph S. Bair, Lifen Cao, Jinming Gao, Xiumei Huang, Xiuquan Luo, Xinpeng Ma, Zachary R. Moore, Elizabeth I. Parkinson
  • Patent number: 10272100
    Abstract: Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 30, 2019
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventor: Du Woon Kim
  • Patent number: 10272101
    Abstract: Particulate ?-glucan is solubilized at elevated pressure and temperature to form soluble ?-glucan. The method is safe and economical and produces a product that is an improved pharmaceutical agent.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 30, 2019
    Assignee: BIOTHERA INC.
    Inventors: Andrew Magee, James Rolke, Ren-der Yang
  • Patent number: 10272102
    Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: April 30, 2019
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Martin Westphal, Silke Baasner
  • Patent number: 10272103
    Abstract: The present invention provides a crosslinked amine and amide polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritis, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: April 30, 2019
    Assignee: Relypsa, Inc.
    Inventors: Jordan Kopping, Paul Mansky, YongQi Mu, Michael James Cope, Elizabeth Goka, Angela Lee, Deidre Madsen, Jun Shao, Kalpesh Biyani, Eric Connor, Scott Hecker, Inez Lees, Grace May, Faleh Salaymeh, Hongmin Zhang, David Bergbreiter
  • Patent number: 10272104
    Abstract: The present invention is anti-itching powder that blocks transmission to stratum corneum and invasion up to epidermal cells by emulsion as a result of further concentration on skin stratum corneum. The emulsion is produced by mixing sweat continuously secreted during rest and sebum. The emulsion becomes a cell disorder composition. Specifically, the anti-itching powder as a fine powder contains main ingredients of aluminum chloride or alum and cyclodextrin. A fine powder as a base is dispersed into and combined with the fine powder. The application of the fine powder over the skin prevents sudden itch without blocking emission and transpiration of water in the sweat from the skin stratum corneum.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: April 30, 2019
    Assignee: Lilac Laboratory Co., Ltd.
    Inventor: Ryoichi Hiraiwa
  • Patent number: 10272105
    Abstract: A composition including a plant medium and a poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The composition may include one or more nutrients. The composition may be in a solid form, a fluid form, or a combination thereof. The poly-oxygenated aluminum hydroxide is soluble in a fluid. In one embodiment, the poly-oxygenated metal hydroxide composition may have particles having a diameter of 212 ?m or less, and which may be homogeneous.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: April 30, 2019
    Assignee: HEMOTEK, LLC
    Inventors: Caree L. Woodmansee, Robert A Woodmansee, John W Woodmansee, Jr., William E. Harmon
  • Patent number: 10272106
    Abstract: A method of treating diabetic retinopathy in a subject in need thereof includes administering to the subject a therapeutically effective amount of one or more agents that act as a trap of reactive aldehydes and/or inhibit diabetes-induced superoxide generation and capillary degeneration regulated by GPCR signaling pathways.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: April 30, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Krzysztof Palczewski, Timothy Kern
  • Patent number: 10272107
    Abstract: The present invention provides methods for treating an inflammatory brain disease and for treating a traumatic brain injury in a human having an inflammatory component applying transdermal pharmaceutical compositions comprising chromium, magnesium, and thiamine as active ingredient compounds that act as neuroprotective iron chelators and brain glucose-uptake enhancement that are suitable for the treatment of traumatic brain injury. The invention further relates to methods of delivering the pharmaceutical compositions that target the brain and/or central nervous system certain novel iron chelators of the type described in the specification.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: April 30, 2019
    Inventor: Kenneth O. Russell
  • Patent number: 10272108
    Abstract: An antimicrobial therapeutic hydrogel composition comprises a pharmaceutical and/or medical grade silver salt, and an Aloe vera gel or extract. The composition could also include stabilizing agents, a non-ionic surfactant, polyol, and hydrophilic hygroscopic polymers. The resulting product has potent antimicrobial activity against bacteria, protozoa, fungi and viruses. The antimicrobial therapeutic composition can serve as a treatment for burns and as a wound/lesion dressing that either donates or receives moisture to provide a physiologic environment for accelerated wound healing and the relief of pain.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: April 30, 2019
    Assignee: CELACARE TECHNOLOGIES, LLC
    Inventors: Kenneth M Yates, Celia A Proctor, Dan H Atchley
  • Patent number: 10272109
    Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 30, 2019
    Assignee: ABT Holding Company
    Inventors: Saverio La Francesca, Anthony E. Ting, Robert J. Deans
  • Patent number: 10272110
    Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 30, 2019
    Assignees: Children's Medical Center Corporation, The General Hospital Corporation
    Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
  • Patent number: 10272111
    Abstract: The present invention relates to cells engineered to express at least one cytokine and at least one antigen which induces the self differentiation of dendritic cell (DC) progenitor cells into functional antigen-presenting induced DC (iDC). Moreover, therapeutic uses of said iDC for regenerating the immune system after transplantation of hematopoietic stem cells are disclosed. Said iDC are also useful for generating mice with a functional endogenously regenerated humanized immune system producing antigen-specific T and B cell responses which can be used as animal models for the study of the human adaptive immune responses.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 30, 2019
    Assignee: Medizinische Hochschule Hannover
    Inventors: Renata Stripecke, Gustavo Salguero-Lopez, Anusara Daenthanasanmak, Arnold Ganser
  • Patent number: 10272112
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: April 30, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Patent number: 10272113
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: April 30, 2019
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze